Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERNAN A SALAZAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538220892
CMS profile
919244
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$713.29

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $359.25 3
Food and Beverage $354.04 20

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $671.70 21
Novartis Pharmaceuticals Corporation $41.59 2

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERNAN A SALAZAR

NPI 1538220892 · CMS profile ID 919244

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $713.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $288.6009/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865861 CMS
Eli Lilly and Company $4.6209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709007629 CMS
Eli Lilly and Company $33.2609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008115 CMS
Eli Lilly and Company $11.0909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008833 CMS
Eli Lilly and Company $44.3409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008835 CMS
Eli Lilly and Company $25.8709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008837 CMS
Eli Lilly and Company $3.3309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008839 CMS
Eli Lilly and Company $23.6409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009169 CMS
Eli Lilly and Company $8.3209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009171 CMS
Eli Lilly and Company $10.9809/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009173 CMS
Eli Lilly and Company $18.4809/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009175 CMS
Eli Lilly and Company $4.4309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009177 CMS
Eli Lilly and Company $8.2509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009343 CMS
Eli Lilly and Company $59.6709/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009345 CMS
Eli Lilly and Company $5.9109/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009347 CMS
Eli Lilly and Company $1.8509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009653 CMS
Eli Lilly and Company $2.0609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009655 CMS
Eli Lilly and Company $10.3509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009833 CMS
Eli Lilly and Company $2.3609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009835 CMS
Eli Lilly and Company $103.4709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010581 CMS
Eli Lilly and Company $0.8209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010583 CMS
Novartis Pharmaceuticals Corporation $20.5008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037539 CMS
Novartis Pharmaceuticals Corporation $21.0904/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $713.29 23
PY2020 $397.53 3
PY2023 $727.75 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,942.29 38
PY2024 Principal investigator $116,310.00 16
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,683,804.34 55
PY2022 Recipient $1,491.00 2
PY2022 Principal investigator $4,307,067.33 117
PY2021 Recipient $201.98 1
PY2021 Principal investigator $8,685,200.41 155
PY2020 Recipient $145.50 1
PY2020 Principal investigator $2,390,117.44 47
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,142,050.05 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $34,607.36 12/31/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721314969
Principal investigator 1 Allergan, Inc. $1,135.25 12/24/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721314071
Principal investigator 1 Janssen Research & Development, LLC $257,815.00 12/22/2020 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719497895
Principal investigator 1 Janssen Research & Development, LLC $257,815.00 12/22/2020 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719497911
Principal investigator 1 Janssen Research & Development, LLC $11,500.00 12/17/2020 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719497893
Principal investigator 1 Janssen Research & Development, LLC $11,500.00 12/17/2020 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults No dispute reported 06/30/2026 719497907
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721311785
Principal investigator 1 Endo Pharmaceuticals Inc. $19,300.00 12/15/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584777
Principal investigator 1 Endo Pharmaceuticals Inc. $1,800.00 11/17/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584771
Principal investigator 1 Allergan, Inc. $1,135.25 11/16/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721307969
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721305027
Principal investigator 1 Allergan, Inc. $1,933.25 10/19/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721303559
Principal investigator 1 Eli Lilly and Company $19,669.00 10/13/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728740203
Principal investigator 1 Endo Pharmaceuticals Inc. $5,900.00 10/13/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584741
Principal investigator 1 Endo Pharmaceuticals Inc. $10,000.00 10/13/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584759
Principal investigator 1 Allergan, Inc. $115.00 09/24/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721300259
Principal investigator 1 Janssen Research & Development, LLC $455,582.50 09/21/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Study for the identification of subjects who are homozygous for the PNPLA3 I148M mutation and have Nonalcoholic fatty liver disease (NAFLD) No dispute reported 06/30/2026 719497667
Principal investigator 1 Janssen Research & Development, LLC $637,815.50 09/21/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Study for the identification of subjects who are homozygous for the PNPLA3 I148M mutation and have Nonalcoholic fatty liver disease (NAFLD) No dispute reported 06/30/2026 719497671
Principal investigator 1 Allergan, Inc. $1,425.00 09/18/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298569
Principal investigator 1 Endo Pharmaceuticals Inc. $5,800.00 09/15/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584729
Principal investigator 1 Eli Lilly and Company $133,584.00 09/03/2020 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 728744211
Principal investigator 1 Eli Lilly and Company $92.77 09/02/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 728748227
Principal investigator 1 Eli Lilly and Company $3,135.24 08/26/2020 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 728734279
Principal investigator 1 DEXCOM, INC. $43,776.00 08/24/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM GLUCOSE MONITORING (CGM) (G7 OUS) No dispute reported 06/30/2026 752065403
Principal investigator 1 DEXCOM, INC. $16,484.00 08/24/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH5) No dispute reported 06/30/2026 752065409
Principal investigator 1 Allergan, Inc. $215.00 08/19/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291187
Principal investigator 1 Endo Pharmaceuticals Inc. $7,000.00 08/18/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS INC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 826584717
Principal investigator 1 Heron Therapeutics, Inc. $1,708.00 08/03/2020 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen No dispute reported 06/30/2026 719645657
Principal investigator 1 Heron Therapeutics, Inc. $13,000.00 08/03/2020 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty No dispute reported 06/30/2026 719645659
Recipient Eli Lilly and Company $145.50 07/31/2020 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728720343
Principal investigator 1 Allergan, Inc. $5,733.25 07/20/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721285309
Principal investigator 1 Allergan, Inc. $1,529.50 06/24/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721281535
Principal investigator 1 DEXCOM, INC. $2,600.00 06/12/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO OUS G7) No dispute reported 06/30/2026 752065045
Principal investigator 1 Heron Therapeutics, Inc. $100,000.00 06/05/2020 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen No dispute reported 06/30/2026 719645655
Principal investigator 1 Allergan, Inc. $6,241.50 05/25/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721276829
Principal investigator 1 Allergan, Inc. $420.00 04/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721273271
Principal investigator 1 Allergan, Inc. $6,569.25 04/20/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271247
Principal investigator 1 DEXCOM, INC. $116,973.00 04/09/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO OUS G7) No dispute reported 06/30/2026 752064857
Principal investigator 1 Allergan, Inc. $5,443.50 03/18/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265463
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262545
Principal investigator 1 DEXCOM, INC. $5,000.00 03/06/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO OUS G7) No dispute reported 06/30/2026 752064709
Principal investigator 1 Allergan, Inc. $20,090.50 02/25/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721260775
Principal investigator 1 DEXCOM, INC. $21,932.00 01/28/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO OUS G7) No dispute reported 06/30/2026 752064379
Principal investigator 1 Allergan, Inc. $20,743.25 01/20/2020 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721248659
Principal investigator 1 DEXCOM, INC. $5,000.00 01/20/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
YSI FEASIBILITY SESSION STUDY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULTS AND PEDIATRICS WITH DIABETES MELLITUS (ALPHA OH5) No dispute reported 06/30/2026 752064293
Principal investigator 1 DEXCOM, INC. $111,644.00 01/08/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
YSI FEASIBILITY SESSION STUDY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULTS AND PEDIATRICS WITH DIABETES MELLITUS (ALPHA OH5) No dispute reported 06/30/2026 752064077
Principal investigator 1 Eli Lilly and Company $3,866.85 01/02/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 728744195
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,032.72 01/01/2020 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO No dispute reported 06/30/2026 721491499